JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Ladarixin sodium (DF 2156A), an investigational small-molecule drug, is a potent, orally bioavailable, non-competitive, dual allosteric inhibitor of CXCR1 and CXCR2 interleukin-8 (IL-8A and IL-8B, respectively). In preclinical studies, ladarixin was shown to prevent and reverse diabetes in NOD mice. The potency of CXCR1/2 inhibition may prevent inflammation- and autoimmunity-mediated damage of pancreatic islets. CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice.
References: Citro A, Valle A, Cantarelli E, Mercalli A, Pellegrini S, Liberati D, Daffonchio L, Kastsiuchenka O, Ruffini PA, Battaglia M, Allegretti M, Piemonti L. CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice. Diabetes. 2015 Apr; 64(4):1329-40. doi: 10.2337/db14-0443. Epub 2014 Oct 14. PubMed PMID: 25315007.
Related CAS #: 849776-05-2 (free) 865625-56-5 (sodium)
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!